TB008

**TB008** is a proprietary proteolysis-targeting chimera (PROTAC) developed by Therabene as a first-in-class CDK9 degrader for oncology applications. It consists of a CDK9-binding moiety linked via an alkyl chain or polyethylene glycol linker to a cereblon E3 ligase recruiter, enabling targeted ubiquitination and proteasomal degradation of CDK9. TB008 demonstrates potent CDK9 kinase inhibition (IC50 3.5 nM), effective degradation in cancer cell lines (e.g., MIA-PaCa-2, NCI-H358), moderate lipophilicity (LogP 2.75), high absorption, and good solubility (LogS -3.83), positioning it as a promising targeted therapy for CDK9-dependent cancers like non-small cell lung carcinoma and pancreatic cancer.[1][7]